X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma/its-end-line-bayers-p13k-aliqoba-and-novos-insulin-levemir-after-two-market-pulls
https://endpts.com/bayer-to-pull-follicular-lymphoma-drug-aliqopa-from-us-market-in-another-blow-to-the-pi3k-inhibitor-space/
https://www.businesswire.com/news/home/20210410005037/en/Investigational-Combination-of-Aliqopa%C2%AE-copanlisib-and-rituximab-Significantly-Increases-Progression-Free-Survival-in-Patients-with-Relapsed-Indolent-non-Hodgkins-Lymphoma
https://www.biopharmadive.com/news/pharming-deal-novartis-cancer-drug-pi3k-immune/561007/
http://www.pharmatimes.com/news/fda_breakthrough_therapy_designation_granted_for_bayers_aliqopa_1289453
https://endpts.com/tg-therapeutics-shares-jump-as-umbralisib-wins-fdas-breakthrough-status/
http://www.pmlive.com/pharma_news/novartis_considers_filings_for_pi3k_drug_in_breast_cancer_1249957
https://www.reuters.com/article/us-novartis-breast-cancer/novartis-trial-win-lifts-profile-of-new-breast-cancer-drug-idUSKCN1L80PM
https://endpts.com/novartis-punts-a-late-stage-pi3k-drug-with-a-worrying-safety-profile-to-one-of-chinas-upstart-biotechs/
https://endpts.com/popular-diet-set-to-be-tested-in-humans-to-see-if-it-can-amp-up-effect-of-weak-pi3k-drugs/
https://endpts.com/roche-dumps-its-phiii-pi3k-effort-on-taselisib-after-researchers-track-poor-survival-edge-harsh-side-effects-for-breast-cancer/
Market Place
Share 
